San Raffaele Diabetes Research Institute, via Olgettina 58, 20132 Milan, Italy.
Semin Immunol. 2011 Jun;23(3):182-94. doi: 10.1016/j.smim.2011.07.007. Epub 2011 Aug 9.
In type 1 diabetes (T1D), insulin-producing pancreatic β-cells are attacked and destroyed by the immune system. Although man-made insulin is life-saving, it is not a cure and it cannot prevent long-term complications. In addition, most T1D patients would do almost anything to achieve release from the burden of daily glucose monitoring and insulin injection. Despite the formation of very large and promising clinical trials, a means to prevent/cure T1D in humans remains elusive. This has led to an increasing interest in the possibility of using T cells with regulatory properties (Treg cells) as a biological therapy to preserve and restore tolerance to self-antigens. In the present review we will attempt to consolidate learning from the past and to describe what we now believe could in the future become a successful Treg-cell based immune intervention in T1D.
在 1 型糖尿病（T1D）中，产生胰岛素的胰腺β细胞被免疫系统攻击和破坏。尽管人工胰岛素是救命的，但它不能治愈疾病，也不能预防长期并发症。此外，大多数 T1D 患者几乎愿意做任何事情来摆脱日常血糖监测和胰岛素注射的负担。尽管已经形成了非常大且有前途的临床试验，但仍难以找到预防/治愈人类 T1D 的方法。这导致人们越来越关注具有调节特性的 T 细胞（Treg 细胞）作为一种生物疗法的可能性，以维持和恢复对自身抗原的耐受性。在本综述中，我们将尝试总结过去的经验，并描述我们现在认为未来可能成为 T1D 中基于 Treg 细胞的免疫干预的成功方法。
